Theranostic probe combined with PD‐1 inhibitor achieves 95% tumor regression in advanced cancer models, suggesting new directions in precision oncology.
The development of theranostic probes with tumor‐specific targeting and high therapeutic efficacy remains a pivotal challenge in precision oncology. Herein, we have successfully developed a new cyclooxygenase‐2 (COX‐2)‐targeted probe compound 2 derived from Rofecoxib. Compound 2 facilitated tumor visualization by a sixfold fluorescence enhancement upon COX‐2 binding, while it exhibited minimal background fluorescence under physiological conditions. Moreover, compound 2 monotherapy achieved 53% tumor regression ( p < 0.01). When combined with a programmed cell death protein 1 (PD‐1) inhibitor (RMP1‐14), concurrent blockade of the COX‐2/prostaglandin E2 (PGE2) and PD‐1/programmed death‐ligand 1 (PD‐L1) axes achieved 95% tumor regression ( p < 0.001). Compound 2 involves activating fluorescence by targeting tumor markers COX‐2 as well as enhancing therapeutic efficacy. We believe this approach could provide insights for advancing cancer diagnosis and treatment technologies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: